"As part of Operation Warp Speed, my administration has manufactured one of the most promising vaccines in advance, and it will be fairly long in advance, as soon as a vaccine is approved, the administration will deliver it to the American people immediately".
American pharmaceutical giant Pfizer said on Friday it would apply for emergency authorisation in the U.S. for its vaccine in late November if safety data pans out. Pfizer is partnering with the German company BioNTech on the research.
Widespread mask use might also mean that when people do get infected, they have less virus in their body which makes them less sick.
Shah said that's just one of the distribution challenges, but nevertheless, they are working out scenarios based on the vaccines now in late-stage trials.
The vaccine also must be proven safe.
State health officials say the first shipment of the vaccine is anticipated for delivery in late 2020 or early 2021 to the state from the U.S. Department of Health and Human Services and the U.S. Department of Defense.
Another leading US contender, Moderna Inc., previously announced the earliest it could seek authorization of its own vaccine would be November 25.
Similar studies in recent weeks have reported on one of the Russian vaccines, along with those from the University of Oxford, Chinese company CanSino, and Moderna.
"In North Dakota, we have a close connection with health care, nonprofits, community groups and others that has strengthened our response to COVID-19", said Kylie Hall with the NDSU Center for Immunization Research and Education and member of the vaccine planning team. Trials of two candidate vaccines - made by Johnson & Johnson and Eli Lilly - were "paused" recently over safety concerns. However, all symptoms they lasted a short time.
But there were few takers outside of Russian Federation, and experts dismissed the announcement as premature.
The announcement may be a disappointment to President Donald Trump, who has been raising expectations that vaccines could be ready around the time of the November 3 presidential election in an apparent bid to boost his faltering electoral prospects. A vaccine could possibly be approved by the Food and Drug Administration as early as late November, but it would take at least several more months before the vaccine would be widely available.
"So let me be clear, assuming positive data, Pfizer will apply for Emergency Authorization Use in the USA soon after the safety milestone is achieved in the third week of November", Pfizer Chief Executive Albert Bourla said, noting that he published the letter to provide greater clarity on the timeline for the vaccine.
"Before approval, all vaccines in the European Union (EU) are evaluated against the same high standards as any other medicine", the EMA said in a statement.